Clinical Trial Source LLC

1. Pfizer Inc. $18,909,355 400 payments
2. Moderna TX, Inc. $17,978,262 176 payments
3. Otsuka Pharmaceutical Development & Commercialization, Inc. $2,699,350 72 payments
4. Eli Lilly and Company $2,160,187 76 payments
5. Sage Therapeutics, Inc. $1,505,108 205 payments
6. Takeda Pharmaceuticals U.S.A., Inc. $1,502,796 259 payments
7. AstraZeneca Pharmaceuticals LP $1,454,376 84 payments
8. Intercept Pharmaceuticals, Inc. $1,083,903 167 payments
9. AbbVie, Inc. $936,109 251 payments
10. Sanofi US Services Inc. $926,694 186 payments

1. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $17,951,888 165 payments
2. A Phase 3 Randomized Doubleblinded Placebocontrolled Trial to Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy $9,150,259 64 payments
3. Phase 1 Openlabel Dosefinding Study to Evaluate Safety Tolerability and Immunogenicity and Phase 23 Placebocontrolled Observerblinded Safety Tolerability and Immunogenicity Study of A Sarscov2 Rna Vaccine Candidate Against Covid19 in Healthy Children and Young Adults $5,549,376 77 payments
4. A Phase 23 Randomized Doubleblind Doubledummy Placebo Controlled Study to Evaluate the Safety and Efficacy of 2 Regimens of Orally Administered PF 07321332Ritonavir in Preventing Symptomatic Sarscov2 Infection in Adult Household Contacts of An Individual With Symptomatic Covid19 $2,341,759 30 payments
5. 1009742 $926,322 108 payments
6. A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Sage-217 in the Treatment of Adult Subjects With Major Depressive Disorder $862,854 65 payments
7. A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3819253 and Ly3832479 in Participants With Mild to Moderate Covid-19 Illness $833,420 4 payments
8. A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tak-994 in Patients With Narcolepsy With Or Without Cataplexy (Narcolepsy Type 1 Or Narcolepsy Type 2) $764,662 71 payments
9. A Phase 23 Placebocontrolled Randomized Observerblind Study to Evaluate the Safety Tolerability and Immunogenicity of A Sarscov2 Rna Vaccine Candidate Bnt162b2 Against Covid19 in Healthy Pregnant Women 18 Years of Age and Older $737,478 48 payments
10. Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $650,642 89 payments

1. Other $59,186 15 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.